TP-0903-102 A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Clinical Trial Grant
Awarded By
Tolero Pharmaceuticals, Inc
Start Date
January 10, 2019
End Date
September 17, 2020
Awarded By
Tolero Pharmaceuticals, Inc
Start Date
January 10, 2019
End Date
September 17, 2020